Pharma Cozies Up to Diagnostic Labs
Last year, the Laboratory, MRI & Dialysis sector posted robust deal volume, relatively speaking. The total of 52 announced transactions was a 58% gain compared with the year before, and better than every year since 2007, when 54 deals were announced (see the chart below). Two of the deals targeting a diagnostic lab or technology were made by major pharmaceutical companies. The common thread we’re seeing as we look back in our database is that these pharma companies are gaining another entry to physician practices, like the camel getting its nose under the tent. The largest deal was OPKO Health’s (NYSE: OPK) $1.47 billion acquisition of Bio-Reference Laboratories (NASDAQ:... Read More »
Nestlé Health Buys into Microbiome Therapy
Nestlé Health Science, a subsidiary of Nestlé (NESN.VX), added to its portfolio of nutrition solutions, diagnostics, devices and drugs last week. The company paid $120 million to Seres Therapeutics (NASDAQ: MCRB) to develop and commercialize its product candidates now in development for the treatment of clostridium difficile (c-diff) infection and inflammatory bowel disease (IBD), outside the United States and Canada. The agreement supports the expansion of Seres’ portfolio in markets outside of the United States and Canada and gives financial support for its ongoing R&D. Seres retains full commercial rights to its entire portfolio of product candidates in the United States and... Read More »
This January Is Pharma M&A Month
Halfway through the month of January 2016, 12 pharmaceutical deals have been announced, with a total of $32.8 billion. You might think that’s a result of the annual JP Morgan Healthcare Summit that’s held every year in the second week of January. That’s only half right. Last year, only nine pharma deals were announced the entire month of January, with six of them in the first two weeks. In 2014, there were 14 pharma deals in January, 11 of which were announced in the first two weeks. The biggest deal in the sector this month, Shire plc’s (NASDAQ: SHPG) $32 billion acquisition of Baxalta Inc. (NYSE: BXLT), was in the works long before the Summit, however. Shire... Read More »
Behavioral Health Care M&A Recap 2015
Behavioral health is a growing national concern, finally, and investors are responding to the growing public attention. Mergers and acquisitions in this healthcare sector rose more than 46% last year, to more than 40 transactions. The two publicly traded, pure-play companies in this area, AAC Holdings (NYSE: AAC) and Acadia Healthcare Company (NASDAQ: ACHC), lead the list of acquirers (six and five announced deals, respectively). Private equity firms were also active acquirers, including Kohlberg & Company, Revelstoke Capital Partners, Flexpoint Ford, Vestar Capital Partners and Shore Point Partners. Many PE portfolio companies have been building behavioral health care... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
